- Home
- LDWY vs GNPX Comparison
LDWY vs GNPX Comparison
Compare LDWY & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LDWY | GNPX |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 6.4M |
| IPO Year | 1991 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LDWY | GNPX |
|---|---|---|
| Price | $5.25 | $2.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 96.6K | ★ 1.6M |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $69,769,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.47 | ★ N/A |
| Revenue Growth | ★ 121.91 | N/A |
| 52 Week Low | $3.11 | $1.71 |
| 52 Week High | $6.19 | $55.00 |
Technical Indicators
Market Signals| Indicator | LDWY | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 72.36 | 43.84 |
| Support Level | $3.52 | $2.10 |
| Resistance Level | $4.99 | $3.11 |
| Average True Range (ATR) | 0.52 | 0.40 |
| MACD | 0.16 | -0.02 |
| Stochastic Oscillator | 94.75 | 8.56 |
Price Performance
Historical ComparisonAbout LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in industries: Specialty Ag, consisting of the Bloomia business.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.